# Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)

> **NCT02668783** · PHASE3 · TERMINATED · sponsor: **Organon and Co** · enrollment: 25 (actual)

## Conditions studied

- Moderate to Severe Primary Dysmenorrhea

## Interventions

- **DRUG:** Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring
- **DRUG:** Placebo vaginal ring
- **DRUG:** Ibuprofen

## Key facts

- **NCT ID:** NCT02668783
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-11
- **Primary completion:** 2016-09-07
- **Final completion:** 2016-09-07
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02668783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02668783, "Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02668783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*